Allergy, Asthma , Immunology

Management of Asthma COPD Overlap Publication date: Available online 31 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Diego Jose Maselli, Nicola Alexander Hanania

Drug reaction with eosinophilia and systemic symptoms (DRESS) and cytomegalovirus colitis Publication date: Available online 31 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Dr Matthew Krummenacher, Dr Tatjana Banovic, Dr Frank Kette, Dr William Smith, Dr Pravin Hissaria

Characterization of Idiopathic Angioedema in a University-Based Allergy/Immunology Practice Publication date: Available online 31 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Daniel L. Rosenberg, Sameer K. Mathur, Ravi K. Viswanathan

The Future Of Omics For Clinical Practice Publication date: Available online 26 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Andrew Long, Bryan Bunning, Matteo Borro, Vanitha Sampath, Kari C. Nadeau Dr. Kari Nadeau: Dr. Nadeau receives grant support from NIAID, Food Allergy Research & Education (FARE), End Allergies Together, Allergenis, Ukko; personal Fees from Regeneron, AstraZeneca, ImmuneWorks, Cour; sponsored research from Novartis, Sanofi, Astellas, Nestle; Sponsored research for clinical trials from Genentech, Aimmune Therapeutics, DBV Technologies, AnaptysBio, Stallergenes-Greer, Regeneron, and Adare Pharmaceuticals; Data and Safety Monitoring Board member at Novartis and NHLBI; co-founded Before Brands, Alladapt Immunotherapeutics, and ForTra; grant awardee for NIAID, NHLBI, NIEHS, and EPA; Director for FARE and World Allergy Organization (WAO) Center of Excellence. All other authors declare no conflict of interest.

Effects of Indoor Particulate Matter Exposure on Daily Asthma Control Publication date: Available online 26 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Syed Hussain, Sarah Parker, Karen Edwards, Joanne Finch, Antoine Jeanjean, Roland Leigh, Sherif Gonem

Preventing iatrogenic gelatin anaphylaxis Publication date: Available online 26 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Yike Jiang, Irene H. Yuan, Emily K. Dutille, Rebecca Bailey, Marcus S. Shaker

Key policies to support asthma medication management for children Publication date: Available online 26 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Sandra E. Zaeh, Meredith C. McCormack, Michelle N. Eakin

Allergy Watch October 2019 Publication date: Available online 25 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): David A. Khan, John J. Oppenheimer, Gerald B. Lee, Stanley M. Fineman

Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making Publication date: Available online 24 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Mauli Desai, John Oppenheimer

Autoimmunity in Common Variable Immunodeficiency Publication date: Available online 23 July 2019 Source: Annals of Allergy, Asthma & Immunology Author(s): Shradha Agarwal, Charlotte Cunningham-Rundles Abstract Objective Common variable immunodeficiency (CVID) is a primary immunodeficiency that is clinically heterogeneous, characterized by both infectious and non-infectious complications. While the hallmark of disease presentation is commonly a history of recurrent sinopulmonary infections, autoimmunity and non-infectious inflammatory conditions are increasing associated with CVID. Data Sources A comprehensive literature search using PubMed of basic science and clinical articles was performed. Study Selections: Articles discussing the association of autoimmunity with primary immunodeficiency, specifically CVID, were selected. Results The most common autoimmune conditions are cytopenias, including immune thrombocytopenia purpura and hemolytic anemia, but organ specific autoimmune/inflammatory complications involving the gastrointestinal, skin, joints, connective tissue, and respiratory tract. In most cases immunoglobulin replacement therapy does not ameliorate or treat these inflammatory complications, and additional immunomodulatory treatments are needed. Conclusion Mechanisms producing these conditions are poorly understood but include cytokine and cellular inflammatory pathways, and loss of tolerance to self-antigens through the multiple signaling molecules and pathways common to tolerance and immune deficiency.